LEADER 03117nam 2200637 a 450 001 9910461322403321 005 20200520144314.0 010 $a1-283-14832-3 010 $a9786613148322 010 $a981-4289-27-2 035 $a(CKB)2670000000095527 035 $a(EBL)737615 035 $a(OCoLC)733048132 035 $a(SSID)ssj0000525922 035 $a(PQKBManifestationID)12186793 035 $a(PQKBTitleCode)TC0000525922 035 $a(PQKBWorkID)10508701 035 $a(PQKB)10697983 035 $a(MiAaPQ)EBC737615 035 $a(WSP)00007498 035 $a(Au-PeEL)EBL737615 035 $a(CaPaEBR)ebr10479900 035 $a(CaONFJC)MIL314832 035 $a(EXLCZ)992670000000095527 100 $a20101215d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aStrong stability preserving Runge-Kutta and multistep time discretizations$b[electronic resource] /$fSigal Gottlieb, David Ketcheson, Chi-Wang Shu 210 $aHackensack, N.J. $cWorld Scientific$dc2011 215 $a1 online resource (189 p.) 300 $aDescription based upon print version of record. 311 $a981-4289-26-4 320 $aIncludes bibliographical references and index. 327 $aPreface; Contents; 1. Overview: The Development of SSP Methods; 2. Strong Stability Preserving Explicit Runge-Kutta Methods; 3. The SSP Coe cient for Runge-Kutta Methods; 4. SSP Runge-Kutta Methods for Linear Constant Coefficient Problems; 5. Bounds and Barriers for SSP Runge-Kutta Methods; 6. Low Storage Optimal Explicit SSP Runge-Kutta Methods; 7. Optimal Implicit SSP Runge-Kutta Methods; 8. SSP Properties of Linear Multistep Methods; 9. SSP Properties of Multistep Multi-Stage Methods; 10. Downwinding; 11. Applications; Bibliography; Index 330 $aThis book captures the state-of-the-art in the field of Strong Stability Preserving (SSP) time stepping methods, which have significant advantages for the time evolution of partial differential equations describing a wide range of physical phenomena. This comprehensive book describes the development of SSP methods, explains the types of problems which require the use of these methods and demonstrates the efficiency of these methods using a variety of numerical examples. Another valuable feature of this book is that it collects the most useful SSP methods, both explicit and implicit, and presen 606 $aRunge-Kutta formulas 606 $aDifferential equations$xNumerical solutions 606 $aStability 608 $aElectronic books. 615 0$aRunge-Kutta formulas. 615 0$aDifferential equations$xNumerical solutions. 615 0$aStability. 676 $a518/.6 700 $aGottlieb$b Sigal$0870544 701 $aKetcheson$b David I$0870545 701 $aShu$b Chi-Wang$021813 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910461322403321 996 $aStrong stability preserving Runge-Kutta and multistep time discretizations$91943402 997 $aUNINA LEADER 01043cam0-22003251i-450 001 990007076440403321 005 20220929123503.0 010 $a88-14-07282-5 035 $a000707644 035 $aFED01000707644 035 $a(Aleph)000707644FED01 100 $a20020430d1998----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ay---n---001yy 200 1 $aLeggi amministrative fondamentali$eannotate con la giurisprudenza della Corte costituzionale, della Cassazione e delle giurisdizioni amministrative$eaggiornamento legislativo$fa cura di G. Pescatore ... [et al.] 210 $aMilano$cGiuffrè$d1998 215 $aVIII, 242 p.$d20 cm 676 $a342.0602632$v21$zita 702 1$aPescatore,$bGabriele 710 01$aItalia$0423419 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990007076440403321 952 $aVI Z 260.A$b36564*$fFGBC 952 $aXXI A 31$b2566-3028$fDDCIC 959 $aDDCIC 959 $aFGBC 996 $aLeggi amministrative fondamentali$9508054 997 $aUNINA LEADER 03515nam 2200625 450 001 9910830371803321 005 20230721005314.0 010 $a1-4443-0333-3 010 $a1-4443-0334-1 035 $a(CKB)1000000000722805 035 $a(EBL)416357 035 $a(OCoLC)476247457 035 $a(SSID)ssj0000104238 035 $a(PQKBManifestationID)11140788 035 $a(PQKBTitleCode)TC0000104238 035 $a(PQKBWorkID)10079636 035 $a(PQKB)11394892 035 $a(MiAaPQ)EBC416357 035 $a(EXLCZ)991000000000722805 100 $a20160805h20092009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntiplatelet therapy in ischemic heart disease /$fStephen D. Wiviott 210 1$aHoboken, New Jersey :$cWiley-Blackwell,$d2009. 210 4$d©2009 215 $a1 online resource (311 p.) 225 1 $aAmerican Heart Association Clinical Series 300 $aIncludes index. 311 $a1-4051-7626-1 327 $aContents; Contributors; Preface; Foreword; PART I: Concepts in Platelet Physiology, Function, and Measurement; 1 Platelet physiology and the role of the platelet in ischemic heart disease; 2 Laboratory assessment of platelet function and the effects of antiplatelet agents; PART II: Pharmacology of Oral Antiplatelet Agents; 3 Cyclooxygenase inhibitors; 4 Aspirin response variability and resistance; 5 P2Y[sub(12)] inhibitors: Thienopyridines and direct oral inhibitors; 6 Thienopyridine response variability and resistance; PART III: Pharmacology of Intravenous Antiplatelet Agents 327 $a7 Pharmacology of intravenous glycoprotein IIb/IIIa antagonists8 Intravenous P2Y[sub(12)] inhibitors; 9 Antiplatelet effects of thrombin inhibitors and fibrinolytic agents; PART IV: Clinical Use of Antiplatelet Agents in Cardiovascular Disease; 10 Antiplatelet therapy in acute coronary syndrome without ST elevation; 11 Antiplatelet therapy in ST-elevation myocardial infarction; 12 Antiplatelet therapy in chronic coronary artery disease; 13 Antiplatelet therapy in peripheral arterial disease; 14 Clinical use of antiplatelet agents in cardiovascular disease: cerebrovascular diseases 327 $aPART V: Special Circumstances15 Antiplatelet therapy and coronary bypass surgery: risks and benefits; 16 Management of antiplatelet therapy for non-cardiac surgery; 17 Antiplatelet therapy and coronary stents; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; R; S; T; U; V; W; Author Disclosure Table 330 $a* Draws from expertise of leaders in antiplatelet therapy* Easy-to-use layout enables rapid browsing* Edited by a member of the prestigious TIMI study group with long-standing experience in the field 410 0$aAmerican Heart Association monograph. 606 $aCoronary heart disease$xChemotherapy 606 $aBlood platelets$xAggregation 606 $aCoronary heart disease$xdrug therapy 615 0$aCoronary heart disease$xChemotherapy. 615 0$aBlood platelets$xAggregation. 615 0$aCoronary heart disease$xdrug therapy. 676 $a616.12306 676 $a616.123061 700 $aWiviott$b Stephen D.$01342498 701 $aWiviott$b Stephen D$01342498 712 02$aAmerican Heart Association. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830371803321 996 $aAntiplatelet therapy in ischemic heart disease$94047776 997 $aUNINA